



10/572 348

5/12

Attorney Docket No.: 6692.204-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Lau et al.

Application No.: TBA

Group Art Unit: TBA

Filed: March 17, 2006

Examiner: TBA

For: Novel GLP-1 Derivatives

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.


While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the International Patent and article references is also enclosed.

The references are as follows:

1. US 2004/0001827
2. WO 99/43361
3. WO 99/43707
4. WO 99/43705
5. WO 98/08872
6. WO 01/51071



101572348

JUN 12 2006

Attorney Docket No.: 6692.204-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Lau et al.

Serial No.: TBA

Group Art Unit: TBA

Filed: March 17, 2006

Examiner: TBA

For: Novel GLP-1 Derivatives

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement
2. Form PTO-1449
3. Copy of References

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on **June 7, 2006**

Rashida Haji
(name of person mailing paper)

Rashida Haji
(signature of person mailing paper)

7. WO 01/04156
8. WO 99/43341
9. WO 02/058725
10. WO 03/087139
11. WO 03/002136
12. Deacon, C.F. et al., Diabetologia, Vol. 41, pp. 271-8 (1998)
13. Holz, G.G. et al., Curr Med Chem, Vol. 10(22), pp. 2471-83 (2003)
14. Knudsen, L.B., J Med Chem., Vol. 43(9), pp. 1664-9 (2000)
15. Kurtzhals, P. et al., Biochem J., Vol. 312(3), pp. 725-31 (1995)
16. Ostrovski, Y.M., Vol. 47(6), pp. 701-7 (1975)
17. Pico, G., Vol. 136(1), pp. 21-6 (1990)
18. Zobel, K. et al., Bioorg Med Chem Lett., Vol. 13, pp. 1513-5 (2003)

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due. However, please charge any fees should they be required, to Novo Nordisk Inc. Deposit Account No. 14-1447.

Respectfully submitted,

Date: June 7, 2006

Richard W. Bork
Richard W. Bork, Reg. No. 36,459
Novo Nordisk Inc.
Customer Number 23650
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE


101572348

Sheet 1 of 1

FORM PTO-1449
(Rev. 3-2001)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Atty. Docket No. 6692.204-US

Serial No. TBA

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(use several sheets if necessary)

Applicant Lau et al.

Filing Date March 17, 2006

Group TBA

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	2004/0001827	06/28/02				

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	99/43361	02/25/99	WO				
	99/43707	02/25/99	WO				
	99/43705	02/25/99	WO				
	98/08872	09/01/97	WO				
	01/51071	01/11/01	WO				
	01/04156	07/12/00	WO				
	99/43341	02/25/99	WO				
	02/058725	01/23/02	WO				
	03/087139	03/27/03	WO				
	03/002136	06/27/02	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Deacon, C.F. et al., Diabetologia, Vol. 41, pp. 271-8 (1998)
		Holz, G.G. et al., Curr Med Chem, Vol. 10(22), pp. 2471-83 (2003)
		Knudsen, L.B., J Med Chem., Vol. 43(9), pp. 1664-9 (2000)
		Kurtzhals, P. et al., Biochem J., Vol. 312(3), pp. 725-31 (1995)
		Ostrovski, Y.M., Vol. 47(6), pp. 701-7 (1975)
		Pico, G., Vol. 136(1), pp. 21-6 (1990)
		Zobel, K. et al., Bioorg Med Chem Lett., Vol. 13, pp. 1513-5 (2003)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.